Loading...
Docoh

Rocket Pharmaceuticals (RCKT)

News

From Benzinga Pro
The Daily Biotech Pulse: Valneva's COVID-19 Vaccine Filing Accepted By EMA, Enanta's RSV Candidate Fails, Orphan Drug Tag For Mersana's Gastric Cancer Candidate
19 May 22
Biotech, Earnings, News, Penny Stocks, Health Care, Contracts, Small Cap, FDA, Management, Insider Trades, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Rocket Pharmaceuticals Presents Top-line Data From Severe Leukocyte Adhesion Deficiency-I Program At The 25Th Annual Meeting Of The American Society Of Gene And Cell Therapy
19 May 22
Biotech, News, FDA, Events, General
— RP-L201 well-tolerated with durable CD18 expression for all patients in Phase 2 pivotal trial — — 100% overall survival in patients at one year after RP-L201 infusion based on Kaplan-Meier estimate
Needham Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $62
17 May 22
News, Price Target, Analyst Ratings
Needham analyst Gil Blum maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and lowers the price target from $75 to $62.
Rocket Pharmaceuticals Presents Clinical Data From Danon Disease, Fanconi Anemia And Pyruvate Kinase Deficiency Programs At The 25Th Annual Meeting Of The American Society Of Gene And Cell Therapy
16 May 22
Biotech, News, Events, General
— RP-A501 for Danon Disease well-tolerated in two pediatric patients with no complement-mediated toxicities reported; efficacy update remains on track for Q3
Rocket Pharmaceuticals Q1 EPS $(0.67) Down From $(0.65) YoY
5 May 22
Earnings, News
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.67) per share. This is a 3.08 percent decrease over losses of $(0.65) per share from the same period last year.
Stocks That Hit 52-Week Lows On Thursday
28 Apr 22
News, Options, Intraday Update, Markets
During Thursday, 849 stocks hit new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
27 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
Wednesday's session saw 784 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
26 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Stocks That Hit 52-Week Lows On Friday
22 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 431 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
21 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Thursday, 236 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
19 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Tuesday, 242 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
14 Mar 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday, 671 companies achieved new lows for the year.
SVB Leerink Maintains Outperform on Rocket Pharmaceuticals, Raises Price Target to $64
24 Feb 22
News, Price Target, Analyst Ratings
SVB Leerink analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and raises the price target from $62 to $64.
Rocket Pharmaceuticals Q4 EPS $(0.69) Up From $(1.08) YoY
24 Feb 22
Earnings, News
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.69) per share. This is a 36.11 percent increase over losses of $(1.08) per share from the same period last year.

Press releases

From Benzinga Pro
Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
19 May 22
Press Releases
— RP-L201 well-tolerated with durable CD18 expression for all patients in Phase 2 pivotal trial — — 100% overall survival in patients at one year after RP-L201 infusion based on Kaplan-Meier estimate — — All patients
Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
16 May 22
Press Releases
— RP-A501 for Danon Disease well-tolerated in two pediatric patients with no complement-mediated toxicities reported; efficacy update remains on track for Q3 — — Sustained genetic correction observed in six
Rocket Pharmaceuticals to Present at UBS Global Healthcare Conference
11 May 22
Press Releases
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need,
Rocket Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Progress
5 May 22
Press Releases
— Continued to advance clinical gene therapy programs for the treatment of Danon Disease, Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I) and Pyruvate Kinase Deficiency (PKD) — — Updates on all four
Rocket Pharmaceuticals to Present at the Bank of America Securities 2022 Global Healthcare Conference
27 Apr 22
Press Releases
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that Kinnari Patel, Pharm.D., MBA,
Rocket Pharmaceuticals to Present at Upcoming Investor Conferences
29 Mar 22
Press Releases
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that Kinnari Patel, Pharm.D., MBA,
Rocket Pharmaceuticals Appoints Fady Malik, M.D., Ph.D., to Board of Directors
14 Mar 22
Press Releases
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the appointment of Fady Malik,
Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance
8 Mar 22
Press Releases
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the appointment of Jessie Yeung as
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial and Operational Results
24 Feb 22
Press Releases
— Positive Phase 1 data from Danon Disease gene therapy trial demonstrated sustained benefit across clinical, functional and biomarker endpoints in all four adult patients with long-term follow up; pediatric cohort data